Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04262-w
Abstract: Switch from zoledronic acid (ZA) to denosumab may increase the risk of medication-related osteonecrosis of the jaw (MRONJ) owing to the additive effect of denosumab on the jawbone and residual ZA activities. We evaluated the… read more here.
Keywords: bone metastases; risk developing; denosumab; zoledronic acid ... See more keywords